The paper details the development and implementation of the Heidelberg Methylation Classifier version 12.8, an advanced diagnostic tool for central nervous system (CNS) tumors. By analyzing DNA methylation profiles, this updated system expands recognized tumor entities from 91 to 184 subclasses, significantly improving the identification of rare and newly discovered cancers. The classifier utilizes a random forest-based model to achieve 95% accuracy, offering clinicians reliable probabilistic confidence scores through a tiered hierarchical structure. Research demonstrates that this molecular approach excels at resolving diagnostic ambiguities where traditional histology fails, often leading to more precise risk stratification and personalized treatment. Furthermore, the authors highlight a global initiative to democratize access to this technology in lower-income regions to address current disparities in neuro-oncology diagnostics.

References:

• Sill M, Schrimpf D, Patel A, et al. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification[J]. Cancer Cell, 2025.